Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Wacker Chemie AG
  6. News
  7. Summary
    WCH   DE000WCH8881

WACKER CHEMIE AG

(WCH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wacker Chemie : Prokarium and Wacker Biotech Sign Manufacturing Contract for Prokarium's Microbial Immunotherapy for Bladder Cancer Patients

10/12/2021 | 05:12am EST
Prokarium and Wacker Biotech Sign Manufacturing Contract for Prokarium's Microbial Immunotherapy for Bladder Cancer Patients

Joint press release by WACKER and Prokarium

London / Amsterdam, Oct 12, 2021

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Wacker Biotech announced today that they had signed a contract for the manufacturing of Prokarium's microbial novel immunotherapy for bladder cancer. Under the terms of the initial agreement, Wacker Biotech will ramp up GMP (Good Manufacturing Practice) production of Prokarium's Salmonella-based immunotherapy at its biotech site in Amsterdam using its LIBATEC® technology.

Wacker Biotech's site in Amsterdam has experience with manufacturing Live Microbial Products (LMPs) since 2006. Fermenters are used to develop and produce LMPs (Photo: WACKER).

Preparations for the start of production, technology transfer and scale-up for a Phase 1 trial are already underway, as announced by the companies. "We are very pleased to work with Wacker Biotech given their deep expertise with live microbial products and GMP production," said Kristen Albright, PharmD, Prokarium's Chief Executive Officer. "This marks an exciting milestone essential to progressing our lead microbial immunotherapy program into clinic."

As a CDMO (Contract Development and Manufacturing Organization), Wacker Biotech will use its LIBATEC® technology platform for Live Microbial Products (LMPs) in the project. The company's site in Amsterdam is a pioneer in the field of LMP production. "With our LIBATEC® platform, Wacker Biotech offers its customers over 15 years' experience in process development and manufacturing pharmaceuticals that contain living microorganisms," said Jörg Lindemann, Managing Director of Wacker Biotech B.V. "The LIBATEC® platform can be used for a wide range of Live Microbial Products and is perfectly suited to support Prokarium with their Salmonella-based immunotherapy."

About Prokarium

Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. The company's pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium's lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based London, UK. For further information, visit www.prokarium.com.

About Wacker Biotech

Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are full-service contract manufacturers of therapeutic proteins, live microbial products (LMPs), vaccines based on microbial systems and plasmid DNA. Wacker Biotech's portfolio extends from strain/process development and analytical testing through to production for clinical and commercial applications. Wacker Biotech maintains three GMP-compliant (Good Manufacturing Practice), FDA- and EMA-certified production plants at its Jena and Halle sites in Germany and in Amsterdam in the Netherlands. The company's most recent acquisition is its San Diego site (Wacker Biotech US Inc.), added in February 2021. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc.are wholly-owned subsidiaries of the Munich-based WACKER Group. For more information visit: www.wacker.com/biologics.

Presspicture
Fermenter Wacker Biotech

Fermenter Wacker Biotech

Order photo
Contact

Media Contact

Wacker Chemie AG
Media Relations & Information
Manuela Dollinger

Tel. +49 89 6279-1629
Send message

Prokarium
Chief Executive Officer
Kristen Albright

info@prokarium.com

close
close

Disclaimer

Wacker Chemie AG published this content on 12 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2021 09:11:14 UTC.


ę Publicnow 2021
All news about WACKER CHEMIE AG
11/30WACKER CHEMIE : Presents Additives for Biodegradable Plastics at the European Bioplastics ..
PU
11/22WACKER CHEMIE AG : Warburg Research reiterates its Neutral rating
MD
11/15WACKER CHEMIE : COMPAMED 2021 - WACKER Presents Silicone Adhesive Gels for Wound Dressings..
PU
11/15WACKER CHEMIE : Staff and WACKER Donate almost Ç60,000 to Flood Relief
PU
11/12WACKER CHEMIE AG : Receives a Buy rating from Barclays
MD
11/10WACKER CHEMIE AG : UBS reiterates its Buy rating
MD
11/04WACKER CHEMIE AG : JP Morgan reaffirms its Neutral rating
MD
11/03WACKER CHEMIE AG : NorldLB remains Neutral
MD
11/03WACKER CHEMIE AG : Receives a Buy rating from UBS
MD
10/29Wacker Chemie AG Reports Earnings Results for the Third Quarter and Nine Months Ended S..
CI
More news
Analyst Recommendations on WACKER CHEMIE AG
More recommendations
Financials
Sales 2021 6 061 M 6 857 M 6 857 M
Net income 2021 766 M 866 M 866 M
Net cash 2021 668 M 755 M 755 M
P/E ratio 2021 9,30x
Yield 2021 3,92%
Capitalization 6 853 M 7 736 M 7 753 M
EV / Sales 2021 1,02x
EV / Sales 2022 0,83x
Nbr of Employees 14 345
Free-Float 28,8%
Chart WACKER CHEMIE AG
Duration : Period :
Wacker Chemie AG Technical Analysis Chart | WCH | DE000WCH8881 | MarketScreener
Technical analysis trends WACKER CHEMIE AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 137,95 €
Average target price 165,83 €
Spread / Average Target 20,2%
EPS Revisions
Managers and Directors
Christian Hartel President & Chief Executive Officer
Peter-Alexander Wacker Chairman-Supervisory Board
Matthias Biebl Member-Supervisory Board
Franz-Josef KortŘm Member-Supervisory Board
Susanne Weiss Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
WACKER CHEMIE AG18.16%7 736
HEXPOL AB (PUBL)25.63%4 049
SHANDONG HEAD CO.,LTD.192.56%3 181
NOLATO AB (PUBL)27.28%3 030
TOKYO OHKA KOGYO CO., LTD.-1.10%2 557
ELKEM ASA3.66%2 006